LPC
PRTK

Loeb Partners Corp’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Loeb Partners Corp’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,000
Closed -$226K – 177
2017
Q3 		$226K Buy
+9,000
New +$209K 0.07% 153
2016
Q4 		– Sell
-10,000
Closed -$130K – 173
2016
Q3 		$130K Hold
10,000
– – 0.05% 145
2016
Q2 		$139K Hold
10,000
– – 0.05% 151
2016
Q1 		$152K Buy
+10,000
New +$153K 0.05% 140

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Loeb Partners Corp's PRTK Position: Q4 2017 in Review

Loeb Partners Corp sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 9,000 shares — an estimated $226K sold.

Loeb Partners Corp first reported a position in PRTK in Q1 2016 and held it in 4 quarters. The position peaked at $226K in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Loeb Partners Corp reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Loeb Partners Corp sold 9,000 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $226K.
  • Loeb Partners Corp first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
  • Loeb Partners Corp's Paratek Pharmaceuticals, Inc. position peaked at $226K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Loeb Partners Corp's 13F filing for Q4 2017, filed 5 Feb 2018.